Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 6/20 | 0.54 |
| ▸ | EGFR | P00533 | 11/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | GAK | O14976 | 2/20 | 0.46 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.45 |
| ▸ | STK17B | O94768 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465424 | 0.88 | MAPT (0.52) | ERBB2EGFRBRAFLCKSRC | |
| SCHEMBL5786009 | 0.86 | EGFR (0.50) | ERBB2EGFRBRAFLCKSRC | |
| SCHEMBL4471668 | 0.84 | SRC (0.61) | ERBB2EGFRBRAFLCKSRC | |
| SCHEMBL4461985 | 0.83 | EGFR (0.60) | ERBB2EGFRBRAFLCKSRC | |
| SCHEMBL4462956 | 0.81 | EGFR (0.76) | ERBB2EGFRLCKSRCKDR | |
| SCHEMBL4458635 | 0.81 | SRC (0.76) | ERBB2EGFRBRAFLCKSRC | |
| SCHEMBL4458762 | 0.81 | EGFR (0.57) | ERBB2EGFRLCKSRCKDR | |
| SCHEMBL4473865 | 0.78 | KDR (0.55) | EGFRLCKSRCKDRGAK | |
| SCHEMBL4471950 | 0.77 | ERBB2 (0.64) | ERBB2EGFRBRAFMAPTMAPK10 | |
| SCHEMBL4466185 | 0.77 | ERBB2 (0.68) | ERBB2EGFRBRAFERBB4ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | claimed |
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1636195-A1 | QUINAZOLINES AND PYRIDO[3,4-D]PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004106308-A1 | QUINAZOLINES AND PYRIDO [3,4-D] PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNY | ERBB2 1183/4885EGFR 166/4885BRAF 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.